Open Label High Dose Ropinirole (Requip) Study for Patients With Parkinson's Disease

Inclusion Criteria: * Patients must give written informed consent prior to any specific study procedures. * Males or females; females of childbearing age who are not currently pregnant must agree to use a medically accepted method of contraception throughout the study. * Age greater than or equal to 25 years. * Patients must be on a maximum dose of dopamine agonist drug (pergolide 4mg/day, pramipexole 4.5 mg/day or ropinirole 24mg/day). * Stable dose of all medications for 4 weeks. Exclusion Criteria: * Current hallucinations. * History of disabling hallucinations or hallucinations in past requiring treatment. * Troublesome edema (swelling). * Unstable depression. * Female who is pregnant or lactating. * Use of an investigational drug with in the last 30 days. * Other inclusion or exclusion criteria to be evaluated by the physician.